Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2010; 31(01): 33-35
DOI: 10.4103/0971-5851.68852
CASE REPORT

Secondary acute myeloid leukemia after successful treatment for osteosarcoma

Rakesh Mittal
Unit of Pediatric Oncology, Department of Medical Oncology, Kuwait Cancer Control Centre, Kuwait
,
N V Ramaswamy
Unit of Pediatric Oncology, Department of Hematology, Kuwait Cancer Control Centre, Kuwait
,
R Pandita
Unit of Pediatric Oncology, Department of Hematology, Kuwait Cancer Control Centre, Kuwait
,
S Al Bahar
Unit of Pediatric Oncology, Department of Hematology, Kuwait Cancer Control Centre, Kuwait
,
N Khalifa
Unit of Pediatric Oncology, Department of Medical Oncology, Kuwait Cancer Control Centre, Kuwait
,
S Omar
Unit of Pediatric Oncology, Department of Medical Oncology, Kuwait Cancer Control Centre, Kuwait
› Author Affiliations Source of Support Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Secondary acute myeloid leukemia (sAML) is a rare complication following chemotherapy for osteogenic sarcoma. However, the exact offending drug is difficult to prove as there is no consistent data. It usually develops 2 years after completion of therapy. We report a case of sAML that developed within 8 months of completing the treatment. The patient was treated with cisplatin, doxorubicin and high-dose methotreaxate followed by surgery (amputation). Eight months after completion of therapy, while on follow-up, he presented with leukocytosis and thrombocytopenia and confirmed to have AML.

Keywords

Acute myeloid leukemia - chemotherapy - osteosarcoma - secondary malignancy


Publication History

Article published online:
19 November 2021

© 2010. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hijiya N, Ness KK, Ribeiro RC, Hudson MM. Acute leukemia as a secondary malignancy in children and adolescents: Current findings and issues. Cancer 2009;115:23-35.
  • 2 Pyatt DW, Aylward LL, Hays SM. Is age an independent risk factor for chemically induced acute myelogenous leukemia in children? J Toxicol Environ Health B Crit Rev 2007;10:379-400.
  • 3 Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998;1400:233-55.
  • 4 Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks. Med Pediatr Oncol 1994;23:86-98.
  • 5 Smith MA, Rubinstein L, Anderson JR, Arthur D, Catalano PJ, Freidlin B, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-77.
  • 6 Pratt CB, Meyer WH, Luo X, Cain AM, Kaste SC, Pappo AS, et al. Second malignant neoplasms occuring in survivors of osteosarcoma. Cancer 1997;80:960-5.
  • 7 Hauben EI, Arends J, Vandenbroucke JP, van Asperen CJ, Van Marck E, Hogendoorn PC. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet 2003;11:611-8.
  • 8 Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, et al. Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol 2006;28:774-80.
  • 9 Aung L, Gorlick RG, Shi W, Thaler H, Shorter NA, Healey JH, et al. Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience.Cancer 2002;95:1728-34.
  • 10 Orazi A, Sozzi G, Delia D, Morandi F, Rottoli L, Cattoretti G. Acute monoblastic leukemia as a second malignancy following chemotherapy for osteogenic sarcoma: A case report. Pediatr Hematol Oncol 1988;5:39-46.
  • 11 Jeha S, Jaffe N, Robertson R. Secondary acute non-lymphoblastic leukemia in two children following treatment with a cis-diamminedichloroplatinum-II-based regimen for osteosarcoma. Med Pediatr Oncol 1992;20:71-4.
  • 12 Kawai A, Sugihara S, Naito N, Ozaki T, Isu K, Hatae Y, et al. Development of acute myeloid leukemia after chemotherapy for osteosarcoma. Clin Orthop Relat Res 2001;391:239-46.
  • 13 Escudero MC, Lassaletta A, Sevilla J, Fernandez-Plaza S, Pιrez A, Diaz MA, et al. Chemotherapy-related secondary acute myeloid leukemia in patients diagnosed with osteosarcoma. J Pediatr Hematol Oncol 2004;26:454-6.
  • 14 Pappo A, Schneider NR, Sanders JM, Buchanan GR. Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma. Cancer 1991;68:1373-5.
  • 15 Beaty O 3 rd , Hudson MM, Greenwald C, Luo X, Fang L, Wilimas JA, et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin′s disease. J Clin Oncol 1995;13:603-9.
  • 16 Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986;53:661-71.
  • 17 Panizo C, Patiρo A, Calasanz MJ, Rifσn J, Sierrasesumaga L, Rocha E. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: Implications of germline TP53 mutations. Med Pediatr Oncol 1998;30:165-9.
  • 18 Schneider DT, Hilgenfeld E, Schwabe D, Behnisch W, Zoubek A, Wessalowski R, et al. Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. J Clin Oncol 1999;17:3226-33.
  • 19 Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004;22:2510-1.
  • 20 Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004;18:120-5.